SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher ...

Canagliflozin is generally well tolerated and improves blood sugar control in children and adolescents with type 2 diabetes, ...

As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) ...

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

Adults with type 2 diabetes who initiate SGLT2 inhibitors within 3 months of a diagnosis of a urinary tract infection have a ...

Mineralys Therapeutics Inc (MLYS) showcases promising trial results and strategic initiatives amid financial challenges and competitive pressures.

Levy reported R&D expenses of $38.3 million for Q2 2025, down from $39.3 million in the prior year period, attributed to the conclusion of the lorundrostat pivotal program, partially offset by ...

The females in my family on my mother's side seem to develop dementia/Alzheimer's on a fairly regular basis. It seems to ...